| scholarly article | Q13442814 |
| P50 | author | Samir S Taneja | Q56516562 |
| P2860 | cites work | Metal mesh stents for ureteral obstruction caused by hormone-resistant carcinoma of prostate | Q33653169 |
| Supportive care, pain management, and quality of life in advanced prostate cancer | Q33653624 | ||
| Docetaxel (Taxotere) in hormone-refractory prostate cancer. | Q33918613 | ||
| Efficacy and morbidity of“channel” turp | Q36802407 | ||
| Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer | Q39413134 | ||
| Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration | Q39442699 | ||
| Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group | Q39444538 | ||
| Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience | Q39466570 | ||
| Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate | Q39547597 | ||
| Spinal cord compression in prostate cancer | Q40403331 | ||
| Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer | Q40785807 | ||
| Endocrine therapy of advanced carcinoma of the prostate | Q40873344 | ||
| Pain management in the patient with prostate cancer | Q40873355 | ||
| A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma | Q43629483 | ||
| A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | Q43784114 | ||
| Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer | Q43784119 | ||
| Management of malignant extrinsic compression of the ureter by simultaneous placement of two ipsilateral ureteral stents | Q43853770 | ||
| Endoscopic ureteroneocystostomy: palliative urinary diversion in advanced prostatic cancer | Q44042753 | ||
| A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting | Q44288944 | ||
| The need for a multidisciplinary approach to cancer care | Q46145019 | ||
| Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment | Q67281520 | ||
| Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP beneficial? | Q68197069 | ||
| Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer | Q71702035 | ||
| Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report | Q72182752 | ||
| The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer | Q72424489 | ||
| Importance of continued testicular suppression in hormone-refractory prostate cancer | Q72576848 | ||
| Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916 | Q73287864 | ||
| Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer | Q73823361 | ||
| Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists | Q74272352 | ||
| Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer | Q74593451 | ||
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | S85-91 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Reviews in urology | Q26853801 |
| P1476 | title | A multidisciplinary approach to the management of hormone-refractory prostate cancer | |
| P478 | volume | 5 Suppl 3 |
Search more.